KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.

Xiaohui Liu, Xia Zang, Kongxin Zhu, Xingcheng Huang, Xiaowen Hu, Zhaofeng Bi, Qi Chen, Hanmin Jiang, Yijun Wang, Changlin Yang, Donglin Liu, Wenhua Zhu, Zizheng Zheng, Yingying Su, Ting Wu, Shoujie Huang, Chunlan Zhuang, Jun Zhang, Ningshao Xia

Nat Commun 16(1) 11187

PMID41407683
PMCIDPMC12711902
DOI10.1038/s41467-025-66188-8
发表日期2025-12-17
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。
摘要

摘要

The durability and protective effect of naturally acquired antibodies against hepatitis E virus (HEV) reinfection and clinical progression remain unclear in humans. In a 103-month longitudinal analysis of 7032 adult placebo recipients (aged 16 to 65 years) from a phase 3 HEV vaccine trial in China, we demonstrated that baseline anti-HEV IgG seropositivity (n = 3194) conferred over 50% higher protection against reinfection compared with seronegative individuals (n = 3838), with this protective effect remaining consistent over 8.5 years. A non-linear dose-response relationship was observed, whereby baseline anti-HEV IgG concentrations ≥0.25 WHO units/mL were associated with at least a 50% reduction in infection risk, with higher baseline antibody levels correlated with a lower risk of infection. Natural immunity provided approximately 70% protection against clinically apparent hepatitis E in the cohort, with 10 symptomatic cases identified over a decade of active surveillance. Six were hospitalized, all of whom were baseline seronegative. These findings establish that natural HEV immunity provides durable, though incomplete, protection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design and flowchart. In the phase 3 clinical study of the hepatitis E vaccine Hecolin ® , 7032 participants from the placebo arm of the immunogenicity subset (participants from Town QD and Town AF) who had valid baseline serostatus data were included in the analysis set for natural infection. Serum samples were collected at baseline (0 m) and scheduled blood collection time points including months 0, 7, 13, 19, 31, 43, 55, 67, 79, 91, and 103, and anti-HEV IgG antibodies were tested. In the PI-A set, the intervals between the paired samples include 6, 7, 12, and 13 months, with a median interval of 12 months. In the OI-A set, the intervals between the two consecutive samples range from 6 to 103 months, with a median interval of 24 months. The presence of HEV infection was determined by the dynamic changes in anti-HEV IgG antibodies across the series of serum samples. Hepatitis E cases were captured through an active hepatitis surveillance system established for the phase 3 clinical trial from 2007 to 2017.
非 KM Figure
Fig. 2Adjusted protection of pre-existing antibodies against HEV infection. The y-axis in the figure represents the protection rate over the entire follow-up period (from month 0 to the specified time point). The error bars in the figure represent the 95% confidence interval of the protection rate. a In the Precise infection analysis (PI-A) set. b In the Overall infection analysis (OI-A) set. A Poisson regression model was utilized to evaluate the relative risk (RR) of the incidence between the groups. The protection rate (%) was calculated as (1 − RR) ×100. The adjusted protection rate was calculated by including age, sex, and township as covariates in the model. Source data are provided as a Source Data file.
非 KM Figure
Fig. 3Cumulative incidence of HEV infection. a In the Precise infection analysis (PI-A) set. b In the Overall infection analysis (OI-A) set. Participants were categorized into seven groups based on baseline anti-HEV IgG concentrations: not detectable (green line), [0.077, 0.25) (light blue line), [0.25, 0.5) (dark blue line), [0.5, 1.0) (light purple line), [1.0, 2.5) (dark purple line), [2.5, 5.0) (pink line), and ≥5.0 WU/mL (orange line). “Not detectable” indicates antibody concentrations below the cut-off of 0.077 WU/mL; for example, [0.077, 0.25) represents concentrations ≥0.077 but <0.25 WU/mL, [0.25, 0.5) represents ≥0.25 but <0.5 WU/mL, and so forth. Cumulative HEV infection incidence was shown for the PI-A set within 55 months and for the OI-A set within 103 months. P -value was calculated by the log-rank test for comparison across all groups. These figures of survival analysis (i.e., Kaplan–Meier) were generated using R software, version 4.5.1.
非 KM Figure